# A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer

> **NCT07676162** · PHASE3 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab
- **DRUG:** Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab

## Key facts

- **NCT ID:** NCT07676162
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-28
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07676162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07676162, "A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07676162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*